<DOC>
	<DOCNO>NCT01420627</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics EZN-2279 patient ADA-deficient combined immunodeficiency currently treat Adagen .</brief_summary>
	<brief_title>EZN-2279 Patients With ADA-SCID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<criteria>1 . Diagnosis ADAdeficient combine immunodeficiency 2 . Stable clinical status receive therapy Adagen® . Patients previously receive gene therapy undergo hematopoietic stem cell transplantation still require Adagen® treatment eligible . The dose Adagen® must stable least 3 month prior study entry . 3 . Have Adagen® Leadin phase study : 1 . Trough plasma ADA activity &gt; 15 μmol/h/mL receive Adagen® 2 . Total erythrocyte dAXP ≤0.02 μmol/mL trough blood sample 4 . Patients parent/guardian must capable understand protocol requirement risk provide write informed assent/consent 1 . Autoimmunity require immunosuppressive treatment 2 . Patients neutralize antiAdagen® antibody screen evaluation . 3 . Severe thrombocytopenia ( platelet count &lt; 50 x 109/L ) 4 . Current participation therapeutic protocol ADAdeficient combine immunodeficiency 5 . Current prior participation another clinical study investigational agent and/or use investigational drug 30 day study entry . 6 . Known planned participation genetherapy study plan duration study 7 . Any condition , opinion PI SigmaTau , make patient unsuitable study 8 . Inability unwillingness administer Adagen® EZN2279 one time per week regimen 9 . Inability comply study protocol 10 . Female patient pregnant lactate 11 . Female patient breastfeed 12 . Female subject childbearing potential use FDA approve birth control method</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>